Loading...
NPI 1053083006 · Morton Grove, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Zenix Labs LLC is a clinical medical laboratory provider located in Morton Grove, Illinois. This profile covers 6 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Zenix Labs LLC |
| Address | 6284 Oakton St |
| City | Morton Grove |
| State | IL |
| ZIP | 60053 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 29, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $1M |
ZENIX LABS LLC appears to operate primarily as a high-volume COVID-19 testing and test-provision practice: the provider’s Medicare billing is dominated by K1034 (provision of nonprescription self-administered, self-collected COVID-19 tests) and its Medicare and Medicaid top codes include U0003, U0005, and G2023 (high-throughput nucleic acid testing and specimen collection). The code mix (K1034, U0003, U0005, G2023) indicates an operational model built around mass testing distribution and laboratory processing rather than diversified clinical laboratory services.
Medicare revenue is extremely concentrated: the top 3 Medicare codes account for 99.7% of the provider’s total Medicare revenue, and K1034 alone represents $3.1M (98.8% of Medicare revenue) with 258.5K claims and a $12 avg paid/claim. K1034 ranks #113 of 30143 providers nationally and is labeled an extreme outlier (100th percentile), signaling this provider is far above typical national volume for that single service.
Medicaid revenue is also concentrated but to a slightly lesser degree: the top 3 Medicaid codes account for 92.6% of total Medicaid revenue, led by U0003 at $590.2K (57.9% of Medicaid revenue, 10.4K claims) and followed by G2023 ($183.8K, 10.8K claims) and U0005 ($168.9K, 8.9K claims). These three codes are all common COVID-19 testing and specimen collection services, reinforcing that Medicaid activity mirrors the provider’s COVID-focused service line.
Payer mix shows Medicare-scale dominance: lifetime Medicare revenue is $3.1M versus $1M in Medicaid, so Medicare represents the larger revenue stream for this provider while Medicaid remains a meaningful secondary payer. The dual-payer footprint means ZENIX LABS has exposure to both federal and state reimbursement environments, but overall financial scale is weighted toward Medicare.
Competitive standing is bifurcated by payer and code: for K1034 the provider is a national-level outlier (rank #113 of 30143; 100th percentile) and functions as a dominant distributor/processor for that specific code, whereas the provider’s other Medicare codes (U0003, U0005, G2023) show typical, unremarkable national volumes (66th, 63th, 56th percentiles respectively). In Medicaid, the provider ranks highly in-state on core codes (U0003 #35 of 350, 90th percentile; G2023 #25 of 396, 94th percentile; U0005 #36 of 210, 83th percentile), indicating a strong state-level presence for PCR testing and specimen collection.
This profile carries concentration risk: reliance on a single Medicare code (K1034 accounting for 98.8% of Medicare revenue) and on three codes for 92.6% of Medicaid revenue suggests revenue sensitivity to changes in demand, reimbursement policy, or coding rules for COVID-related testing. Any material shift in payment rates or utilization for these specific codes could disproportionately affect the provider’s revenue base.
Operational footprint is high-volume and transaction-oriented: K1034 shows 258.5K Medicare claims, and Medicaid shows multi-thousand claim volumes for U0003 (10.4K), G2023 (10.8K), and U0005 (8.9K), consistent with a business model focused on mass testing, specimen collection, and high-throughput laboratory processing rather than low-volume specialty testing. The average paid/claim figures (e.g., $12 for K1034 on Medicare, $57 for U0003 on Medicaid) further support a high-quantity, low-per-test reimbursement structure.
TENURE: ZENIX LABS LLC’s NPI was enumerated on 2021-09-29 (~5 years ago), indicating it is a relatively recent entrant that scaled rapidly into high-volume COVID testing services during/after the pandemic period. The recent enrollment date combined with outsized volumes on a narrow set of COVID-related codes suggests rapid operational scaling focused on pandemic-related demand.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 258,500 | $10 | $3.1M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 270 | $70 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 270 | $30 | $6.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 270 | $20 | $6.3K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 60 | $40 | $2.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 20 | $50 | $950 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 6 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 10,360 | $60 | $590.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10,810 | $20 | $183.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 8,890 | $20 | $168.9K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 2,300 | $30 | $71.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 60 | $40 | $2.6K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 580 | $1 | $1.7K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 35 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 36 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 25 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 43 | 550 | 240 | $40 | $42.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 538 | 890 | 90 | $40 | $35K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 32 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Zenix Labs LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Dehan Home Medical Equipment | IL | Durable Medical Equipment & Medical Supplies | $0 | $5.9M |
| Alejandra Rodriguez-paez | IL | Rheumatology Physician | $2.5M | $90 |
| Ami Kothari | IL | Rheumatology Physician | $2.5M | $180 |
| Edward Kaplan | IL | Hematology & Oncology Physician | $2.4M | $91.6K |
| Ermin Arriola | IL | Physical Medicine & Rehabilitation Physician | $2.4M | $730 |
| Chinyoung Park | IL | Rheumatology Physician | $1.8M | $350 |
| Roop Gupta | IL | Gastroenterology Physician | $237.3K | $1.3M |
| Illinois Sports Medicine & Orthopedic Surgery Center, LLC | IL | Ambulatory Surgical Clinic/Center | $1.1M | $0 |
| Teresa Sosenko | IL | Rheumatology Physician | $863.6K | $0 |
| Ejaz Shamim | IL | Diagnostic Radiology Physician | $34.5K | $540.6K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.